ACTU
USDActuate Therapeutics Inc. Common stock
السعر في الوقت الحقيقي
مخطط الأسعار
المقاييس الرئيسية
مقاييس السوق
الافتتاح
$6.500
الأعلى
$6.660
الأدنى
$6.461
الحجم
0.02M
أساسيات الشركة
القيمة السوقية
153.2M
الصناعة
التكنولوجيا الحيوية
البلد
United States
إحصاءات التداول
متوسط الحجم
0.07M
البورصة
NGM
العملة
USD
نطاق 52 أسبوعاً
أخبار ذات صلة
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics with a Buy and maintains $20 price target.
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
أسهم ذات صلة
ابق على اطلاع
تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.